Enhancing the Stability and Solubility of the Glucocorticoid Receptor Ligand-Binding Domain by High-Throughput Library Screening

Journal of Molecular Biology

Volumn 403, Issue 4, 2010, Pages 562-577

  Seitz, Tobias ^a   Thoma, Ralf ^b   Schoch, Guillaume A ^b   Stihle, Martine ^b   Benz, Jörg ^b   D'Arcy, Brigitte ^b   Wiget, Andrea ^b   Ruf, Armin ^b   Hennig, Michael ^b   Sterner, Reinhard ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b Discovery Technologies   (Switzerland)

Author keywords

FACS; Folding reporter; GFP; Glucocorticoid receptor; Library screening

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; GLUCOCORTICOID RECEPTOR; MALTOSE BINDING PROTEIN; APRIL PROTEIN; GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; LIGAND;

ARTICLE; BINDING SITE; CONFORMATIONAL TRANSITION; DRUG DESIGN; ESCHERICHIA COLI; EUKARYOTE; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE MICROSCOPY; FOLLOW UP; GENE EXPRESSION; GENE ISOLATION; GENE LIBRARY; HIGH THROUGHPUT SCREENING; LIGAND BINDING; MOLECULAR CLONING; MOLECULAR LIBRARY; NONHUMAN; PLASMID; PRIORITY JOURNAL; PURIFICATION; SOLUBILITY; STRUCTURE ANALYSIS; THERMOSTABILITY; X RAY ANALYSIS; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; FLOW CYTOMETRY; GENETICS; HUMAN; IN VITRO STUDY; MOLECULAR GENETICS; MOUSE; MUTAGENESIS; NUCLEOTIDE SEQUENCE; PROTEIN CONFORMATION; PROTEIN ENGINEERING; PROTEIN STABILITY; PROTEIN TERTIARY STRUCTURE; SEQUENCE HOMOLOGY; STATIC ELECTRICITY; X RAY CRYSTALLOGRAPHY;

ESCHERICHIA COLI; EUKARYOTA;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; BASE SEQUENCE; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; ESCHERICHIA COLI; FLOW CYTOMETRY; GENE LIBRARY; GREEN FLUORESCENT PROTEINS; HUMANS; IN VITRO TECHNIQUES; LIGANDS; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS; PROTEIN CONFORMATION; PROTEIN ENGINEERING; PROTEIN STABILITY; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, GLUCOCORTICOID; RECOMBINANT FUSION PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID; SOLUBILITY; STATIC ELECTRICITY; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 77957969243     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2010.08.048     Document Type: Article

References (52)

1. Reichardt H.M., Tronche F., Berger S., Kellendonk C., Schutz G. New insights into glucocorticoid and mineralocorticoid signaling: lessons from gene targeting. Adv. Pharmacol. 2000, 47:1-21.
2. Giguere V., Hollenberg S.M., Rosenfeld M.G., Evans R.M. Functional domains of the human glucocorticoid receptor. Cell 1986, 46:645-652.
3. Heitzer M.D., Wolf I.M., Sanchez E.R., Witchel S.F., DeFranco D.B. Glucocorticoid receptor physiology. Rev. Endocr. Metab. Disord. 2007, 8:321-330.
4. Dittmar K.D., Pratt W.B. Folding of the glucocorticoid receptor by the reconstituted Hsp90-based chaperone machinery. The initial hsp90·p60·hsp70-dependent step is sufficient for creating the steroid binding conformation. J. Biol. Chem. 1997, 272:13047-13054.
5. Savory J.G., Hsu B., Laquian I.R., Giffin W., Reich T., Hache R.J., Lefebvre Y.A. Discrimination between NL1- and NL2-mediated nuclear localization of the glucocorticoid receptor. Mol. Cell. Biol. 1999, 19:1025-1037.
6. Newton R. Molecular mechanisms of glucocorticoid action: what is important?. Thorax 2000, 55:603-613.
7. Schoch G.A., D'Arcy B., Stihle M., Burger D., Bär D., Benz J., et al. Molecular switch in the glucocorticoid receptor: active and passive antagonist conformations. J. Mol. Biol. 2010, 395:568-577.
8. Jacobson P.B., von Geldern T.W., Ohman L., Osterland M., Wang J., Zinker B., et al. Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes. J. Pharmacol. Exp. Ther. 2005, 314:191-200.
9. Laan R.F., Jansen T.L., van Riel P.L. Glucocorticosteroids in the management of rheumatoid arthritis. Rheumatology (Oxford) 1999, 38:6-12.
10. Barnes P.J. Therapeutic strategies for allergic diseases. Nature 1999, 402:B31-B38.
11. Renner K., Ausserlechner M.J., Kofler R. A conceptual view on glucocorticoid-induced apoptosis, cell cycle arrest and glucocorticoid resistance in lymphoblastic leukemia. Curr. Mol. Med. 2003, 3:707-717.
12. Schäcke H., Docke W.D., Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol. Ther. 2002, 96:23-43.
13. Scapin G. Structural biology and drug discovery. Curr. Pharm. Des. 2006, 12:2087-2097.
14. Bledsoe R.K., Montana V.G., Stanley T.B., Delves C.J., Apolito C.J., McKee D.D., et al. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 2002, 110:93-105.
15. Eijsink V.G., Bjork A., Gaseidnes S., Sirevag R., Synstad B., van den Burg B., Vriend G. Rational engineering of enzyme stability. J. Biotechnol. 2004, 113:105-120.
16. Roodveldt C., Aharoni A., Tawfik D.S. Directed evolution of proteins for heterologous expression and stability. Curr. Opin. Struct. Biol. 2005, 15:50-56.
17. Khersonsky O., Rosenblat M., Toker L., Yacobson S., Hugenmatter A., Silman I., et al. Directed evolution of serum paraoxonase PON3 by family shuffling and ancestor/consensus mutagenesis, and its biochemical characterization. Biochemistry 2009, 48:6644-6654.
18. Maxwell K.L., Mittermaier A.K., Forman-Kay J.D., Davidson A.R. A simple in vivo assay for increased protein solubility. Protein Sci. 1999, 8:1908-1911.
19. Sieber V., Martinez C.A., Arnold F.H. Libraries of hybrid proteins from distantly related sequences. Nat. Biotechnol. 2001, 19:456-460.
20. 8-barrel protein designed from identical half barrels. J. Mol. Biol. 2007, 372:114-129.
21. Waldo G.S., Standish B.M., Berendzen J., Terwilliger T.C. Rapid protein-folding assay using green fluorescent protein. Nat. Biotechnol. 1999, 17:691-695.
22. Kawasaki M., Inagaki F. Random PCR-based screening for soluble domains using green fluorescent protein. Biochem. Biophys. Res. Commun. 2001, 280:842-844.
23. Pedelacq J.D., Piltch E., Liong E.C., Berendzen J., Kim C.Y., Rho B.S., et al. Engineering soluble proteins for structural genomics. Nat. Biotechnol. 2002, 20:927-932.
24. Li P., Guan H., Li J., Lin Z. Heterologous expression, purification, and characterization of cytochrome P450sca-2 and mutants with improved solubility in Escherichia coli. Protein Expression Purif. 2009, 65:196-203.
25. Sarkar C.A., Dodevski I., Kenig M., Dudli S., Mohr A., Hermans E., Plückthun A. Directed evolution of a G protein-coupled receptor for expression, stability, and binding selectivity. Proc. Natl Acad. Sci. USA 2008, 105:14808-14813.
26. Bershtein S., Tawfik D.S. Advances in laboratory evolution of enzymes. Curr. Opin. Chem. Biol. 2008, 12:151-158.
27. Yang G., Withers S.G. Ultrahigh-throughput FACS-based screening for directed enzyme evolution. ChemBioChem 2009, 10:2704-2715.
28. Gupta R.D., Tawfik D.S. Directed enzyme evolution via small and effective neutral drift libraries. Nat. Methods 2008, 5:939-942.
29. Cormack B.P., Valdivia R.H., Falkow S. FACS-optimized mutants of the green fluorescent protein (GFP). Gene 1996, 173:33-38.
30. Ho S.N., Hunt H.D., Horton R.M., Pullen J.K., Pease L.R. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 1989, 77:51-59.
31. Drummond D.A., Iverson B.L., Georgiou G., Arnold F.H. Why high-error-rate random mutagenesis libraries are enriched in functional and improved proteins. J. Mol. Biol. 2005, 350:806-816.
32. Suino-Powell K., Xu Y., Zhang C., Tao Y.G., Tolbert W.D., Simons S.S., Xu H.E. Doubling the size of the glucocorticoid receptor ligand binding pocket by deacylcortivazol. Mol. Cell. Biol. 2008, 28:1915-1923.
33. Kauppi B., Jakob C., Farnegardh M., Yang J., Ahola H., Alarcon M., et al. The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism. J. Biol. Chem. 2003, 278:22748-22754.
34. Biggadike K., Bledsoe R.K., Hassell A.M., Kirk B.E., McLay I.M., Shewchuk L.M., Stewart E.L. X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain. J. Med. Chem. 2008, 51:3349-3352.
35. Madauss K.P., Bledsoe R.K., McLay I., Stewart E.L., Uings I.J., Weingarten G., Williams S.P. The first X-ray crystal structure of the glucocorticoid receptor bound to a non-steroidal agonist. Bioorg. Med. Chem. Lett. 2008, 18:6097-6099.
36. Adams P.D., Grosse-Kunstleve R.W., Hung L.W., Ioerger T.R., McCoy A.J., Moriarty N.W., et al. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr. Sect. D 2002, 58:1948-1954.
37. Ricketson D., Hostick U., Fang L., Yamamoto K.R., Darimont B.D. A conformational switch in the ligand-binding domain regulates the dependence of the glucocorticoid receptor on Hsp90. J. Mol. Biol. 2007, 368:729-741.
38. O'Neil K.T., DeGrado W.F. A thermodynamic scale for the helix-forming tendencies of the commonly occurring amino acids. Science 1990, 250:646-651.
39. Lehmann M., Loch C., Middendorf A., Studer D., Lassen S.F., Pasamontes L., et al. The consensus concept for thermostability engineering of proteins: further proof of concept. Protein Eng. 2002, 15:403-411.
40. Amin N., Liu A.D., Ramer S., Aehle W., Meijer D., Metin M., et al. Construction of stabilized proteins by combinatorial consensus mutagenesis. Protein Eng. Des. Sel. 2004, 17:787-793.
41. Reetz M.T., Carballeira J.D., Vogel A. Iterative saturation mutagenesis on the basis of B-factors as a strategy for increasing protein thermostability. Angew. Chem. Int. Ed. Engl. 2006, 45:7745-7751.
42. Chalfie M., Tu Y., Euskirchen G., Ward W.W., Prasher D.C. Green fluorescent protein as a marker for gene expression. Science 1994, 263:802-805.
43. Crameri A., Whitehorn E.A., Tate E., Stemmer W.P. Improved green fluorescent protein by molecular evolution using DNA shuffling. Nat. Biotechnol. 1996, 14:315-319.
44. Yang T.T., Cheng L., Kain S.R. Optimized codon usage and chromophore mutations provide enhanced sensitivity with the green fluorescent protein. Nucleic Acids Res. 1996, 24:4592-4593.
45. Sarkar G., Sommer S.S. The ″ megaprimer″ method of site-directed mutagenesis. Biotechniques 1990, 8:404-407.
46. a/dT crossing a single thermally induced pH junction in a BGE with high dpH/dT. Electrophoresis 2009, 30:1501-1509.
47. Kabsch W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J. Appl. Crystallogr. 1993, 26:795-800.
48. McCoy A.J., Grosse-Kunstleve R.W., Adams P.D., Winn M.D., Storoni L.C., Read R.J. Phaser crystallographic software. J. Appl. Crystallogr. 2007, 40:658-674.
49. Emsley P., Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. Sect. D 2004, 60:2126-2132.
50. Murshudov G.N., Vagin A.A., Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. Sect. D 1997, 53:240-255.
51. Collaborative Computational Project Number 4 The CCP4 suite: programs for protein crystallography. Acta Crystallogr. Sect. D 1994, 50:760-763.
52. Bricogne G., Blanc E., Brandl M., Flensburg C., Keller P., Paciorek W., et al. BUSTER, Version 2.8.0 2009, Global Phasing Ltd., Cambridge, UK.